Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

Clinical Trial ID NCT01505114

Rank	Title	Journal	Year	PubWeight™‹?›
1	Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.	N Engl J Med	2010	50.17
2	Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.	J Infect Dis	2011	1.70
3	CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.	Drug Metab Dispos	2014	0.98
4	Next-generation oral preexposure prophylaxis: beyond tenofovir.	Curr Opin HIV AIDS	2012	0.92
5	Current perspectives in HIV post-exposure prophylaxis.	HIV AIDS (Auckl)	2014	0.89
6	A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).	PLoS One	2015	0.89
7	Models for predicting effective HIV chemoprevention in women.	J Acquir Immune Defic Syndr	2015	0.87
8	Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.	Clin Chim Acta	2014	0.86
9	Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.	J Control Release	2015	0.83
10	Using Cognitive Interviews to Enhance Measurement in Empirical Bioethics: Developing a Measure of the Preventive Misconception in Biomedical HIV Prevention Trials.	AJOB Empir Bioeth	2015	0.75